With 10.2 million shares changed hands, the volume of the stock remained heavier than its average volume of 5.32 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $3.805 whereas the lowest price it dropped to was $3.2. The 52-week range on SANA shows that it touched its highest point at $12.00 and its lowest point at $1.52 during that stretch. It currently has a 1-year price target of $10.75. Beta for the stock currently stands at 1.23.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SANA was up-trending over the past week, with a rise of 107.43%, but this was up by 55.13% over a month. Three-month performance dropped to -9.02% while six-month performance fell -42.92%. The stock lost -45.25% in the past year, while it has gained 122.70% so far this year. A look at the trailing 12-month EPS for SANA yields -1.41 with Next year EPS estimates of -0.87. For the next quarter, that number is -0.25. This implies an EPS growth rate of 17.68% for this year and 27.22% for next year.
Float and Shares Shorts:
At present, 223.11 million SANA shares are outstanding with a float of 122.41 million shares on hand for trading. On 2024-12-31, short shares totaled 37.1 million, which was 1662.0001000000002 higher than short shares on 1732838400. In addition to Dr. Steven D. Harr M.D. as the firm’s President, CEO & Director, Ms. Susan Wyrick serves as its Acting CFO, Treasurer, Principal Accounting Officer and Senior VP of Finance & Accounting.
Institutional Ownership:
Through their ownership of 0.92443 of SANA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, SANA reported revenue of $0.0 and operating income of -$61761000.0. The EBITDA in the recently reported quarter was -$57704000.0 and diluted EPS was -$0.25.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SANA since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SANA analysts setting a high price target of 15.0 and a low target of 7.0, the average target price over the next 12 months is 9.8. Based on these targets, SANA could surge 313.22% to reach the target high and rise by 92.84% to reach the target low. Reaching the average price target will result in a growth of 169.97% from current levels.
Analysts have provided yearly estimates in a range of -$1.1432 being high and -$1.27023 being low. For SANA, this leads to a yearly average estimate of -$1.20183. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
